Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis Viral Infections, Non-HIV Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me